BioCryst is a commercial-stage biotech company with US headquarters in Durham, North Carolina. Its European headquarters is in Dublin, Ireland, and its Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world, including the UK.

BioCryst is committed to improving the lives of people living with complement-mediated and other rare diseases. It uses its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases.

BioCryst has commercialised it’s first product for hereditary angioedema (HAE) and is also advancing a pipeline of small-molecule and protein therapies.

BioCryst is committed to operating its business responsibly and sustainably, focusing on activities and initiatives that make the biggest difference and have the most impact on improving patients’ health and well-being. The company’s unique culture reflects this commitment to making a difference. Making a difference and being a different kind of company is so important that it is one of the four metrics by which the Board of Directors assess the annual company performance.

For more information, please visit www.biocryst.co.uk